Biopelle Revenue and Competitors

Biopelle, Inc., the aesthetic subsidiary of Ferndale Pharma Group, Inc., is a worldwide leader in the development and distribution of clinically proven skincare products. Biopelle is committed to helping aesthetic professionals deliver evidence-based, patented technologies that target multiple metabolic pathways to address demanding skin and deliver visible results. Delivering high-quality, professional products through licensed Healthcare Providers, Biopelle's brands cover “a global spectrum of skin care” through its two main pillars: biopelle (including Retriderm, Tensage Growth Factor and Tensage Stem Cell with Cellpro™ Technology - a NEW pathway of rejuvenation) and PRESCRIBEDsolutions, the only multi-tasking customizable skincare line with boosters. About the Ferndale Pharma Group: Founded in 1897, the J.F. Hartz Company provided surgical instruments, medical supplies, and equipment to the medical profession. Years later the name was changed to Ferndale Surgical and Laboratories. In 1975, the company, then called Ferndale Laboratories, Inc., embarked on a mission to grow from a local pharmaceutical manufacturer to a healthcare company with national recognition. In 2004, Ferndale Laboratories, Inc. reorganized to form the Ferndale Pharma Group, Inc., the holding company for a number of healthcare specialty companies, including: Biopelle®, Inc., Ferndale Healthcare, Inc., Eloquest Healthcare®, Inc., Ferndale Laboratories, Inc. and Ferndale Pharmaceuticals Ltd. Within this organizational structure, our subsidiaries are able to rapidly capitalize on opportunities to advance our businesses by providing stakeholders (healthcare professionals, patients, business partners, and associates) with medical solutions that enable patients to live healthier lives. We remain dedicated to taking a leadership role in providing information, brands, and services to facilitate patient care.